FANAPT (iloperidone) by Vanda Pharmaceuticals is unknown. First approved in 2009.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
FANAPT (iloperidone) is an oral atypical antipsychotic approved in 2009 for schizophrenia treatment. It works through dopamine D2 and serotonin 5-HT2 receptor antagonism, with an active metabolite (P88) that maintains similar receptor binding properties. The exact mechanism remains incompletely characterized but demonstrates efficacy in psychotic disorder management.
The product is at peak lifecycle stage with stable Medicare spending (~$93M annually) and modest claim volume (~44K), suggesting a mature, stable but not high-growth brand with moderate team requirements.
unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Atypical Antipsychotic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Worked on FANAPT at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on FANAPT offers stable, mature-stage pharmaceutical experience in a competitive therapeutic area with focus on commercial excellence and patient adherence rather than innovation or launch dynamics. Career growth may be limited by the product's peak lifecycle stage and approaching LOE, with emphasis on operational efficiency and competitive positioning.